Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ST14 | Q9Y5Y6 | 3/20 | 0.65 |
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 2/20 | 0.41 |
| ▸ | MMP8 | P22894 | 2/20 | 0.41 |
| ▸ | MMP14 | P50281 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4209153 | 0.86 | ST14 (0.85) | ST14LOXL2HRH3MMP2MMP9 | |
| SCHEMBL100121 | 0.83 | LOXL2 (0.52) | ST14LOXL2MAOB | |
| SCHEMBL3171767 | 0.82 | RAF1 (0.60) | — | |
| SCHEMBL28006451 | 0.79 | ST14 (0.74) | ST14LOXL2HRH3MMP2MMP9 | |
| SCHEMBL103621 | 0.79 | LMNA (0.61) | ST14LOXL2LTA4HCYP2A6 | |
| SCHEMBL7041332 | 0.78 | LTA4H (0.42) | ST14LTA4HMMP2 | |
| SCHEMBL12806612 | 0.78 | RAB9A (0.46) | LTA4HMMP2 | |
| SCHEMBL41000 | 0.78 | — | — | |
| SCHEMBL8540552 | 0.78 | LMNA (0.47) | LTA4H | |
| Hydrochloric Acid SCHEMBL4375241 | 0.78 | ST14 (0.59) | ST14LOXL2HRH3MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9585891-B2 | Alpha hydroxy amides | MERCK PATENT GMBH (DE) | 2017-03-07 | — | — | US | disclosed |
| US-20150250792-A1 | ALPHA HYDROXY AMIDES | MERCK PATENT GMBH (DE) | 2015-09-10 | — | — | US | disclosed |
| EP-2900633-A1 | ALPHA HYDROXY AMIDES | Merck Patent GmbH (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-20130158076-A1 | Methylene Urea Derivatives | MERCK PATENT GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158076-A1 | Methylene Urea Derivatives | MERCK PATENT GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158076-A1 | Methylene Urea Derivatives | MERCK PATENT GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-8410143-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| US-8410143-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| US-8410143-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| EP-2426122-A1 | Methylene urea derivative as RAF kinasse inhibitors | Merck Patent GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| US-7589112-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2009-09-15 | — | — | US | disclosed |
| US-20060199844-A1 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2006-09-07 | — | — | US | disclosed |
| EP-1562905-A2 | METHYLENE UREA DERIVATIVES AS RAF-KINASE INHIBITORS | MERCK PATENT GmbH (DE) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004037789-A2 | METHYLENE UREA DERIVATIVES AS RAF-KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | BRAF, RAF1, CMPK1 | ST14 2500/4885LOXL2 4354/4885HRH3 2286/4885 |
| US-20060199844-A1 | Methylene urea derivatives | BRAF, RAF1, CMPK1 | ST14 2500/4885LOXL2 4354/4885HRH3 2286/4885 |
| US-20130158076-A1 | Methylene Urea Derivatives | BRAF, RAF1, CMPK1 | ST14 2500/4885LOXL2 4354/4885HRH3 2286/4885 |
| US-20150250792-A1 | ALPHA HYDROXY AMIDES | HCAR1, NAA40, HCAR2 | ST14 4128/4885LOXL2 3652/4885HRH3 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.